Junshi Biosciences Announces Acceptance of NDA for VV116 in China
SHANGHAI, China, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that the new drug application (“NDA”) for Deuremidevir Hydrobromide Tablets (project code: JT001/VV116, “VV116”), an oral nucleoside analog anti-SARS-CoV-2 drug, has been accepted by the National Medical Products Administration (the “NMPA”) for the treatment of the coronavirus disease 2019 (“COVID-19”).
About Junshi Biosciences
Founded in December 2012, Junshi Biosciences (HKEX: 1877; SSE: 688180) is an innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapeutics. The company has established a diversified R&D pipeline comprising over 50 drug candidates, with five therapeutic focus areas covering cancer, autoimmune, metabolic, neurological, and infectious diseases. Junshi Biosciences was the first Chinese pharmaceutical company that obtained marketing approval for anti-PD-1 monoclonal antibody in China. Its first-in-human anti-BTLA monoclonal antibody for the treatment of various cancers was the first in the world to be approved for clinical trials by the FDA and NMPA and has since entered Phase Ib/II trials in both China and the US. Its anti-PCSK9 monoclonal antibody was the first in China to be approved for clinical trials by the NMPA.
In the face of the pandemic, Junshi Biosciences’ response was strong and immediate, joining forces with Chinese and international scientific research institutions and enterprises to develop an arsenal of drug candidates to combat COVID-19, taking the initiative to shoulder the social responsibility of Chinese pharmaceutical companies by prioritizing and accelerating COVID-19 R&D. Among the many drug candidates is JS016 (etesevimab), China’s first neutralizing fully human monoclonal antibody against SARS-CoV-2 and the result of the combined efforts of Junshi Biosciences, the Institute of Microbiology of the Chinese Academy of Science and Lilly. JS016 administered with bamlanivimab has been granted Emergency Use Authorizations (EUA) in over 15 countries and regions worldwide. As of December 3 2021, over 700,000 patients have been treated with bamlanivimab or bamlanivimab and etesevimab, potentially preventing more than 35,000 hospitalizations and at least 14,000 deaths. Meanwhile, VV116, a new oral nucleoside analog anti-SARS-CoV-2 drug designed to hinder virus replication, is in global Phase III clinical trials. The JS016 and VV116 programs are a part of the company’s continuous innovation for disease control and prevention of the global pandemic.
Junshi Biosciences has more than 3,100 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing, Guangzhou, etc). For more information, please visit: http://junshipharma.com.
Junshi Biosciences Contact Information
+ 86 021-6105 8800
+ 86 021-6105 8800
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
NNIT A/S: The Danish Business Authority has issued a decision requiring NNIT to update its accounting treatment of earn-out payments in the annual reports for 2020 and 202128.1.2023 17:18:54 CET | Press release
The Danish Business Authority has conducted a compliance review of NNIT A/S’ annual reports as stated in company announcement 12/2022. Following dialogue with NNIT, the Danish Business Authority has made a final decision affirming that the earn out payment related to the acquisition of Excellis Health Solutions should not be included in capitalized acquisition costs and goodwill, but instead expensed as remuneration as the earn out is in part subject to the selling shareholders’ continued employment during the accrual period. In consequence, NNIT is required to update its accounting treatment of earn-out payment in the annual reports from goodwill to special items as outlined below. A similar approach will be applied to the recognition of earn out payments for other acquisitions, including SCALES, Valiance Partner, HGP Group, SL Controls and prime4services. The technical changes to historical accounting policies will have no impact on total cash flow or the planned divestment of NNIT’s
Inside information: Digitalist Group’s subsidiary Digitalist Finland Oy has signed a term sheet for acquiring Walker & Handson Oy28.1.2023 13:00:00 CET | Press release
Digitalist Group Plc Inside information January 28nd, 2023 at 14:00 Inside information: Digitalist Group’s subsidiary Digitalist Finland Oy has signed a term sheet for acquiring Walker & Handson Oy Digitalist Group Plc (“Digitalist Group”) and its fully-owned subsidiary Digitalist Finland Oy have signed a term sheet (“LOI”) to an agreement (“Transaction”) in which Digitalist Finland Oy would acquire Walker & Handson Oy (“W&H”) to strengthen the management and tech & design business in Digitalist Finland Oy. In the intended Transaction Digitalist Finland Oy would acquire all shares in W&H through share exchange by issuing new Digitalist Finland Oy’s shares in a direct share issue to W&H representing approximately 10% of all shares in Digitalist Finland Oy after completion of the Transaction. The owner of W&H Jussi Hermunen will at the same time take over the position of Managing Director of Digitalist Finland Oy. Mr Jussi Hermunen would bring in solid experience of leading teams and bus
Hexagon Agility launches next generation Mobile Pipeline® modules with deliveries to Certarus28.1.2023 10:20:00 CET | Press release
28 January 2023: As previously disclosed, Hexagon Agility®, a business of Hexagon Composites, signed a multi-year agreement in March 2021 with Certarus, a leading full-service provider of bulk gas transport, to supply newly designed TITAN 450 Mobile Pipeline® modules. Hexagon Agility’s TITAN 450 modules represent the next generation of gas distribution modules and will be used to transport compressed and renewable natural gas (CNG/RNG) throughout North America. Under this agreement, Hexagon Agility has received a new USD 25.6 million (approx. NOK 253 million) order representing the inaugural order of Hexagon Agility’s new TITAN 450 modules. “We are proud to receive our first order for TITAN 450 from Certarus,” said Miguel Raimao, Vice President of Mobile Pipeline at Hexagon Agility. “Over 90% of the TITAN platform has been redesigned. The new TITAN 450 delivers 25% greater gas capacity, while being 20% lighter in the same 40-foot length. We appreciate our long-standing relationship wit
Brasilianska konkurrensmyndigheten godkänner försäljningen av Maha Energy Brasil27.1.2023 21:20:00 CET | Pressemelding
Maha Energy AB (publ) meddelar att brasilianska konkurrensmyndigheten (CADE) har, utan förbehåll, godkänt försäljningen av Maha Energy Brasil Ltda. till PetroRecôncavo S.A. Överlåtelseavtalet för försäljning av hela Mahas andel i Bolagets brasilianska dotterbolag offentliggjordes den 28 december och försäljningens genomförande villkorades av sedvanliga förbehåll, varav ett var godkännande av den brasilianska konkurrensmyndigheten. Denna information är sådan information som Maha Energy AB (publ) är skyldigt att offentliggöra enligt EU:s marknadsmissbruksförordning. Informationen lämnades, genom ovanstående kontaktpersons försorg, för offentliggörande den 27 januari, 2023 kl.21:20 CET För ytterligare information, kontakta: Paulo Thiago Mendonça, VD Telefon: +46 8 611 05 11 E-post: firstname.lastname@example.org Bernardo Guterres, CFO Telefon: +46 8 611 05 11 E-post: email@example.com Kort om Maha Maha Energy AB (publ) är ett listat, internationellt uppströmsolje- och gasbolag vars affärsverksamhet
Brazilian antitrust authority approves the sale of Maha Energy Brasil27.1.2023 21:20:00 CET | Press release
Maha Energy AB is pleased to announce that the Brazilian antitrust authority (CADE) has approved, without restrictions, the sale of Maha Energy Brasil Ltda. to PetroRecôncavo S.A. The quota purchase agreement for the sale of the entirety of Maha’s stake in its Brazilian subsidiary was announced on December 28, 2022, with its closing subject to other customary precedent conditions, the approval by the Brazilian antitrust authority being one of them. This information is such information as Maha Energy AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 21:20 CET, 27 January 2023 For more information, please contact: Paulo Thiago Mendonça, CEO Phone: +46 8 611 05 11 E-mail: firstname.lastname@example.org Bernardo Guterres, CFO Phone: +46 8 611 05 11 E-mail: email@example.com About Maha Maha Energy AB (publ) is a listed, international upstream oil and gas company whose